| 2026-08-14 | Press release | Bicara Therapeutics Announces Inducement Grant under Nasdaq Listing Rule 5635(c)(4) |
| 2026-08-11 | Press release | Bicara Therapeutics Reports Second Quarter 2026 Progress and Announces Strategic Leadership Transitions Marking Next Era |
| 2026-08-10 | Presentation | Corporate Presentation - August 2026 |
| 2026-08-04 | Press release | Bicara Therapeutics to Report Second Quarter 2026 Financial Results and Business Updates on August 11, 2026, at 8:30 AM |
| 2026-07-28 | Press release | Bicara Therapeutics Announces Appointments of Jeremy Bender and Christy Oliger to Board of Directors |
| 2026-07-02 | Press release | Bicara Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) |
| 2026-05-22 | Presentation | American Society of Clinical Oncology Update – May 2026 |
| 2026-05-21 | Press release | Ficerafusp Alfa Plus Pembrolizumab Demonstrated Differentiated Three-Year Overall Survival and Deep Responses Driven by |
| 2026-05-13 | Press release | Bicara Therapeutics Announces Inducement Grant under Nasdaq Listing Rule 5635(c)(4) |
| 2026-05-11 | Press release | Bicara Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update |
| 2026-05-04 | Press release | Bicara Therapeutics to Report First Quarter 2026 Financial Results and Business Updates on May 11, 2026, at 8:30 AM ET |
| 2026-04-03 | Press release | Bicara Therapeutics Announces Inducement Grant under Nasdaq Listing Rule 5635(c)(4) |
| 2026-03-30 | Press release | Bicara Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update |
| 2026-03-23 | Press release | Bicara Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results and Business Updates on March 30, 2026 |
| 2026-02-19 | Press release | Ficerafusp Alfa 2000mg Q2W Demonstrates Deep, Durable Responses in 1L R/M HPV-Negative HNSCC and Supports Development of |
| 2026-01-12 | Press release | Bicara Therapeutics Announces Phase 3 Optimal Dose and Provides 2026 Corporate Outlook |
| 2025-12-01 | Press release | Bicara Therapeutics Announces Publication of an Abstract with Preliminary Phase 1b Expansion Cohort Data Evaluating 750m |
| 2025-10-13 | Press release | Bicara Therapeutics Announces Ficerafusp Alfa Granted Breakthrough Therapy Designation by U.S. FDA for 1L HPV-Negative R |
| 2025-06-01 | Press release | Bicara Therapeutics Demonstrates Deep and Durable Responses with Ficerafusp Alfa Plus Pembrolizumab in 1L HPV-Negative R |
| Press release | Bicara Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update |
| 2025-02-11 | Press release | Bicara Therapeutics Announces First Patients Enrolled in FORTIFI-HN01, a Pivotal Phase 2/3 Clinical Trial of Ficerafusp |
| 2025-01-27 | Press release | Bicara Therapeutics Presents Phase 1/1b Dose Expansion Results with Ficerafusp Alfa in Advanced Squamous Cancer of the A |
| 2024-06-27 | Press release | Bicara Therapeutics Reports Updated Interim Phase 1/1b Data of Ficerafusp Alfa (BCA101) in 1L HPV-negative Recurrent/Met |
| 2023-11-08 | Press release | Bicara Therapeutics to Present at Upcoming November Investor Conferences |
| 2023-10-23 | Press release | Bicara Therapeutics Presents Updated Interim Data from Ongoing Phase 1/1b Study of BCA101 in 1L HPV-negative Recurrent/M |
| 2023-06-05 | Press release | Bicara Therapeutics’ First-in-class Bifunctional EGFR/TGF-β Inhibitor, BCA101, Demonstrates 65% ORR in Combination with |
| 2023-06-01 | Press release | Bicara Therapeutics to Present at the 2023 Jefferies Global Healthcare Conference |
| 2023-04-26 | Press release | Bicara Therapeutics Announces Oral Presentation of Head and Neck Cancer Dose Expansion Data from Phase 1/1b Study of BCA |
| 2023-04-04 | Press release | Bicara Therapeutics to Present Preclinical Data from Clinical-Stage Bifunctional Antibody Program, BCA101, at AACR Annua |
| 2023-01-04 | Press release | Bicara Therapeutics to Present at 41st Annual J.P. Morgan Healthcare Conference |
| 2022-11-07 | Press release | Bicara Therapeutics Presents Preclinical Data for Precision Immunocytokine, BCA356, at Society for Immunotherapy of Canc |
| 2022-09-10 | Press release | Bicara Therapeutics Presents New Data from Ongoing Phase 1/1b Trial of Lead First-in-Class Bifunctional Program, BCA101, |
| 2022-09-08 | Press release | Bicara Therapeutics to Host Webinar to Review Latest Clinical Trial Data for BCA101 |
| 2022-08-18 | Press release | Bicara Therapeutics to Present Clinical Data from Lead Precision Tumor Modulator Program, BCA101, at ESMO Congress 2022 |
| 2022-06-03 | Press release | Bicara Therapeutics Presents Data from Dose Escalation Portion of Ongoing Phase 1/1b Trial of Lead Bifunctional Program, |
| 2022-05-18 | Press release | Bicara Therapeutics to Present Clinical Data from Lead Bifunctional Antibody Program, BCA101, at ASCO 2022 Annual Meetin |
| 2022-02-22 | Press release | Bicara Therapeutics Initiates Dose Expansion Arm of Phase 1/1b Clinical Study of BCA101 in Disease-Specific Cohorts |
| 2022-01-06 | Press release | Bicara Therapeutics to Present at 40th Annual J.P. Morgan Healthcare Conference |